Wegovy Pill Approved in the UK: Everything You Need to Know About the Once-Daily Weight Loss Tablet

The UK has officially approved the oral form of Wegovy-a landmark moment for obesity treatment. Here's what it means, who can access it, and how it compares to injections.

The Medicines and Healthcare products Regulatory Agency (MHRA) has greenlit the Wegovy pill (oral semaglutide), making the UK the first country in Europe to approve it. If you've been hesitant about weight-loss injections, or simply want a more convenient route to clinically-backed treatment, this approval changes the landscape dramatically.

At Rightangled, we've been following oral GLP-1 developments closely-and if you're in the US, you can already access Wegovy semaglutide tablets right now through our partner platform Medetone.

What Is the Wegovy Pill?

The Wegovy pill is the oral tablet form of semaglutide-the same active ingredient found in the once-weekly Wegovy injection. Rather than a weekly self-injection, patients take a single tablet once daily, on an empty stomach, with a small amount of plain water.

Semaglutide is a GLP-1 receptor agonist, a class of medicines that mimic a natural gut hormone released after eating. By activating GLP-1 receptors, it reduces hunger signals, promotes fullness, and helps the body regulate calorie intake-without requiring willpower alone.

Related reading: What Are GLP-1 Medications? A Plain-English Guide

Why Is This a Big Deal?

The approval has been described as a "landmark" moment by Emil Kongshoj Larsen, Executive Vice President at Novo Nordisk, the manufacturer. The UK becomes the first European country to license the pill-ahead of most of Europe and with broader regulatory backing than many anticipated.

Around 15 million people in the UK live with obesity, yet only a fraction have ever accessed treatment. The injection form already has over 1.6 million UK users, but surveys show that roughly one in five people who considered weight-loss medication were put off by needles. An oral option removes that barrier entirely.

Interest has been extraordinary. Online provider Numan reportedly amassed a 55,000-person waiting list within days of the news breaking.

Who Is Eligible?

The Wegovy pill can be prescribed to adults who meet either of these criteria:

• BMI of 30 or above (classified as obese)
  
• BMI of 27-29.9 (classified as overweight) with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or sleep apnoea

This mirrors the eligibility criteria already used for the Wegovy injection and aligns with standard clinical thresholds for obesity treatment.

Check your eligibility now: Rightangled Weight Loss Consultation

How Does the Pill Compare to the Injection?

Both the injection and the tablet use semaglutide, but there are meaningful differences worth understanding:

Clinical trial data (the OASIS 4 trial, 307 adults over 64 weeks) showed participants taking 25mg oral semaglutide alongside lifestyle support lost an average of 16.6% of their body weight, compared to just 2.2% on placebo. That's a result that comfortably rivals many surgical interventions.

The injectable form does show slightly higher weight loss figures-up to 20.7%-but for many patients, the difference is outweighed by the convenience and comfort of an oral option.

Also compare: Wegovy vs Mounjaro: Which Is Right for You?

How to Take the Wegovy Pill Correctly

The pill requires a specific morning routine to work properly. Because semaglutide is a peptide molecule, it needs a carrier compound (SNAC) to survive stomach acid-and that process is sensitive to food and liquid interference.

Step-by-step:

1. Take the tablet first thing in the morning, before eating or drinking anything
2. Swallow whole with no more than 120ml (4oz) of plain water
3. Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
4. Never crush, cut, chew, or dissolve the tablet

Miss this window and the medication may not absorb effectively. This is the main practical consideration that distinguishes it from most daily tablets.

Dosing and Titration

Doses range from 1.5mg to 25mg, with patients stepping up gradually:

• Start at 1.5mg, remain for at least one month before increasing
• Titrate upward through 4mg, 9mg, and eventually 25mg
• Patients already on 2.4mg semaglutide injections can switch directly to the 25mg tablet

Slow titration reduces the risk of side effects-particularly nausea-which are most common in the first few weeks as your body adjusts.

Side Effects to Know About

Oral semaglutide shares a similar side-effect profile with the injectable form. Most are gastrointestinal and tend to ease as the body adapts:

Common (usually temporary):

• Nausea and vomiting
• Diarrhoea or constipation
• Stomach discomfort and bloating
• Heartburn or reflux
• Fatigue or dizziness

Serious (seek medical attention):

• Severe abdominal pain (possible pancreatitis)
• Neck lumps or hoarseness (potential thyroid concern-covered by a boxed warning)
• Signs of gallbladder issues (upper stomach pain, fever, jaundice)
• Mood changes or depression

As with all prescription medications, the Wegovy pill is a prescription-only medicine and should only be started under clinical supervision.

Related: Managing GLP-1 Side Effects: What Actually Helps

Is the Wegovy Pill Available on the NHS?

Not yet. The MHRA approval means it can now be prescribed privately in the UK-through providers like online clinics, pharmacies, and digital health platforms. High street names including Boots, Morrisons, and Superdrug are expected to stock it within weeks.

NHS availability requires a separate assessment by NICE (National Institute for Health and Care Excellence), which can only begin once Novo Nordisk formally submits evidence for appraisal. That process has not yet been initiated, though discussions with the UK Government are ongoing. NHS access could still be months away.

Privately, the pill is expected to cost around £225 per month in the UK-approximately £35 less per month than the Wegovy injection.

Already Available in the US-Right Now

If you're based in the United States, you don't need to wait. Wegovy semaglutide tablets are available now through our US partner, Medetone-a registered New York pharmacy operating under board registration number 042076.

👉 Get Wegovy Tablets in the US-from $149/month at Medetone

The process is straightforward:

1. Complete a 2–3 minute online eligibility consultation
2. Receive doctor approval and a free prescription within 24 hours
3. Same-day shipping, with next-day delivery across New York

Strengths available: 1.5mg, 4mg, 9mg, and 25mg.

What's Coming Next: Orforglipron (Foundayo)

The Wegovy pill won't be alone for long. Eli Lilly-the manufacturer of Mounjaro-has developed a rival oral GLP-1 called Orforglipron, marketed as Foundayo.

Trial data (ATTAIN-1, 3,127 adults over 72 weeks) showed participants on the 36mg dose lost an average of 11.2% of body weight-slightly lower than oral semaglutide, but still clinically meaningful. Orforglipron was approved in the US in April 2026, with a UK decision expected later in 2026.

Crucially, Orforglipron does not require the same strict fasting protocol as oral semaglutide-it may suit patients who find the morning routine difficult to maintain.

Read more: Orforglipron vs Oral Semaglutide: The Full Comparison

Expert Voices on the Approval

Leading clinicians have welcomed the pill's approval, with important nuances:

Professor Naveed Sattar, University of Glasgow: "The approval of the once-daily oral form of Wegovy is welcome news for people living with obesity, particularly those who would prefer not to use injections."

Dr Simon Cork, Anglia Ruskin University, noted that oral formulations are likely to be more attractive but reminded patients that clinical trials show "slightly inferior levels of weight loss compared to injectable forms, particularly Mounjaro." He added that without the need for complex injectable pen systems, the pill will likely be cheaper.

The approval of the Wegovy pill in the UK is a genuine turning point for obesity medicine. It opens the door for millions of people who would never have considered injections, at a price point that undercuts the existing injectable treatment.

The evidence is clear: at the 25mg maintenance dose, patients can expect meaningful weight loss-around 17% of body weight over roughly 64 weeks-alongside lifestyle support. That's not a miracle, but it is a clinically significant, medically supervised intervention.

Whether you're in the UK waiting for private access, or already in the US and ready to start, the oral GLP-1 era has arrived.

Want to be amongst the first?

The Wegovy pill is MHRA-approved and private prescriptions are opening up across the UK shortly. If you'd rather not wait, you can reserve your tablets now and be first in line the moment stock is available, no rushing, no queues.

UK patients: Join the Rightangled waitlist for oral semaglutide

Already in the US? It's available right now from $149/month with free consultation and same-day shipping.
Order today at Medetone →

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any prescription medication.